DRMA — Dermata Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 10.8 | 6.24 | 7.44 | 3.16 | 7.52 |
| Net Total Receivables | — | 0.013 | 0.008 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 11.6 | 6.94 | 7.98 | 3.53 | 7.86 |
| Total Assets | 11.6 | 6.94 | 7.98 | 3.53 | 7.86 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 1.52 | 0.923 | 1.62 | 1.97 | 1.64 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.52 | 0.923 | 1.62 | 1.97 | 1.64 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 10.1 | 6.02 | 6.36 | 1.56 | 6.22 |
| Total Liabilities & Shareholders' Equity | 11.6 | 6.94 | 7.98 | 3.53 | 7.86 |
| Total Common Shares Outstanding |